Quantcast

NICE recommends Takhzyro injection as an option for preventing recurrent attacks of hereditary angioedema (HAE)

NICE has recommended the use of Takhzyro subcutaneous injection as an option for preventing recurrent attacks of hereditary angioedema (HAE) in people aged 12 and older, within their final appraisal document (FAD), Takeda UK said in a press release Wednesday.

Read more

NICE’s approval of Merck’s Erbitux combination gives more choice for mCRC patients in England

English wild-type metastatic colorectal cancer (mCRC) patients are getting more choice to a first-line effective treatment, as the UK National Institute for Health and Care Excellence (NICE) gave a positive Final Appraisal Determination (FAD) recommending the routine National Health Service (NHS) use of Merck’s Erbitux (cetuximab) in combination with either Folfiri or Folfox.

Read more